{"id":20157,"date":"2022-12-15T17:45:13","date_gmt":"2022-12-15T12:15:13","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=20157"},"modified":"2024-09-18T13:15:19","modified_gmt":"2024-09-18T07:45:19","slug":"medtech-news-for-biogx-stryker-dexcom-agilent","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biogx-stryker-dexcom-agilent","title":{"rendered":"BioGX\u2019s \u2018pixl\u2019 Portable qPCR Platform; Stryker\u2019s Citrefix Suture Anchor System; Boston Scientific to Acquire Majority Stake of Acotec Scientific; FDA Approved the Dexcom G7 CGM System; Agilent\u2019s NSCLC Liquid Biopsy Companion Diagnostic Test Approval; ClearPoint Neuro\u2019s Prism&#x2122; Neuro Laser Therapy"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0e2e38a9615\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0e2e38a9615\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biogx-stryker-dexcom-agilent\/#BioGX_Announced_Ex-US_Commercial_Launch_of_%E2%80%98pixl%E2%84%A2_Portable_qPCR_Platform\" >BioGX Announced Ex-US Commercial Launch of \u2018pixl&#x2122;\u2019 Portable qPCR Platform<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biogx-stryker-dexcom-agilent\/#Stryker_launched_Citrefix%E2%84%A2_Suture_Anchor_System\" >Stryker launched Citrefix&#x2122; Suture Anchor System&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biogx-stryker-dexcom-agilent\/#FDA_Approved_the_Next-Generation_Dexcom_G7_Continuous_Glucose_Monitoring_CGM_System\" >FDA Approved the Next-Generation Dexcom G7 Continuous Glucose Monitoring (CGM) System&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biogx-stryker-dexcom-agilent\/#First_Patient_Enrolled_in_Glioblastoma_Trial_Using_ClearPoint_Prism%E2%84%A2_Neuro_Laser_Therapy\" >First Patient Enrolled in Glioblastoma Trial Using ClearPoint Prism&#x2122; Neuro Laser Therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biogx-stryker-dexcom-agilent\/#Boston_Scientific_Announced_Strategic_Investment_to_Acquire_Majority_Stake_of_Acotec_Scientific_Holdings_Limited\" >Boston Scientific Announced Strategic Investment to Acquire Majority Stake of Acotec Scientific Holdings Limited&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biogx-stryker-dexcom-agilent\/#Agilent_Resolution_ctDx_FIRST_Receives_FDA_Approval_as_a_Liquid_Biopsy_Companion_Diagnostic_Test_for_Advanced_Non-small_Cell_Lung_Cancer\" >Agilent Resolution ctDx FIRST Receives FDA Approval as a Liquid Biopsy Companion Diagnostic Test for Advanced Non-small Cell Lung Cancer<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-biogx-announced-ex-us-commercial-launch-of-pixl-portable-qpcr-platform\"><span class=\"ez-toc-section\" id=\"BioGX_Announced_Ex-US_Commercial_Launch_of_%E2%80%98pixl%E2%84%A2_Portable_qPCR_Platform\"><\/span><strong>BioGX Announced<\/strong> <strong>Ex-US Commercial Launch of \u2018pixl&#x2122;\u2019 Portable qPCR Platform<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> December 8, 2022, <\/strong>BioGX, a global provider of easy molecular diagnostic solutions, announced the Ex-US commercial release of BioGX&#8217;s portable pixl&#x2122;<strong> <\/strong>qPCR real-time PCR platform for use with BioGX CE-IVD approved assays.&nbsp;<\/p>\n\n\n\n<p>This opens up access to the world and complements the recent US FDA EUA expanded usage of Xfree&#x2122; COVID-19 Direct RT-PCR on pixl.<\/p>\n\n\n\n<p>A tabletop 4-channel, 16-well RT-PCR apparatus with integrated results interpretation on a touchpad-sized screen, the pixl instrument offers quick turnaround times for batches of up to 16 samples.&nbsp;<\/p>\n\n\n\n<p><em>S<\/em>hazi Iqbal, Ph.D., CEO of BioGX said, \u201c<em>pixl, combined with our unique Xfree chemistry, offers a low-cost direct-sample-to-answer PCR solution on a portable, compact device. pixl will provide broader access to clinical laboratories for decentralized PCR testing, enabling faster, better, low-cost near-patient molecular diagnostics.\u201d<\/em><\/p>\n\n\n\n<p>As per DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/polymerase-chain-reaction-market\"><strong>Polymerase Chain Reaction Market<\/strong><\/a><strong>\u201d report, <\/strong>the global polymerase chain reaction market was valued at <strong>USD 4.90 billion<\/strong> in 2021 and is expected to grow at a CAGR of <strong>8.66% <\/strong>to reach<strong> USD 8.04 billion<\/strong> by <strong>2027<\/strong>. The factors driving the market for polymerase chain reaction include the increasing prevalence of infectious diseases caused by viruses, bacteria, fungi, and other pathogens, including tuberculosis, HIV AIDS, and others, increasing <a href=\"https:\/\/www.delveinsight.com\/report-store\/clinical-diagnostics-market\"><strong>application of PCR in clinical diagnostics<\/strong><\/a>, and the latest technological advancements to enhance the accuracy of PCR among others.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-stryker-launched-citrefix-suture-anchor-system\"><span class=\"ez-toc-section\" id=\"Stryker_launched_Citrefix%E2%84%A2_Suture_Anchor_System\"><\/span><strong>Stryker launched Citrefix&#x2122; Suture Anchor System&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>December 13, 2022<\/strong>, Stryker, launched a disposable suture anchor system named Citrefix&#x2122;, which is made up of award-winning bioresorbable material Citregen&#x2122; capable of mimicking the chemistry and structure of native bone.&nbsp;<\/p>\n\n\n\n<p>When used in orthopedic surgical procedures, Citregen&#x2122; allows the healing of grafted tissue and helps in the growth of healthy bone.&nbsp;<\/p>\n\n\n\n<p>The complete sterile-packed set comes with a cartridge with a preloaded implant and eyelet, a drill bit, a drill guide, and a pre-assembled inserter.<\/p>\n\n\n\n<p>Michael Rankin, Vice President of marketing and medical education for Stryker\u2019s Foot &amp; Ankle business, said<em>, \u201cOur customers will now benefit from the expanded use of one of the most innovative bioresorbable materials available for use in foot and ankle procedures.\u201d <\/em>He further<em> <\/em>added,<em> \u201cCitrefix\u2019s unique suture anchor system is the next step in our expanding Citregen portfolio.\u201d<\/em><\/p>\n\n\n\n<p><em>\u201cBy leveraging Citregen\u2019s unique material properties, Citrefix introduces design features that greatly increase its pull-out strength compared to other suture anchors,\u201d <\/em>said<em> <\/em>Wayne Berberian, M.D., an orthopedic surgeon at the Ankle &amp; Foot Institute in Maywood, N. J. He further said,<em> \u201cAt the same time, the Citregen material benefits patients\u2019 recovery since it is more easily accepted by the body, so they heal without suffering from the chronic inflammation that may occur with other bioresorbable suture anchors.\u201d<\/em><\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/foot-and-ankle-devices-market\"><strong>Foot and Ankle Devices Market<\/strong><\/a>\u201d report, the global foot and ankle devices market was valued at <strong>USD 5.94 billion<\/strong> in <strong>2021<\/strong>, growing at a CAGR of <strong>7.69%<\/strong> during the forecast period from 2022 to 2027, to reach <strong>USD 9.26 billion<\/strong> by <strong>2027<\/strong>. The foot and ankle devices market is estimated to register positive revenue growth primarily due to the <a href=\"https:\/\/www.delveinsight.com\/report-store\/osteoarthritis-market\"><strong>increasing prevalence of bone-related disorders<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetes-epidemiology-forecast\"><strong>rising diabetes-related complications<\/strong><\/a>, increasing cases of accidents, trauma, sports, and other injuries, along with the rising geriatric population. Moreover, the increasing focus of companies on developing technologically advanced foot and ankle devices is likely to propel the market for foot and ankle devices in the upcoming years.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approved-the-next-generation-dexcom-g7-continuous-glucose-monitoring-cgm-system\"><span class=\"ez-toc-section\" id=\"FDA_Approved_the_Next-Generation_Dexcom_G7_Continuous_Glucose_Monitoring_CGM_System\"><\/span><strong>FDA Approved the Next-Generation Dexcom G7 Continuous Glucose Monitoring (CGM) System&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> December 8, 2022,<\/strong> DexCom, Inc., the global leader in real-time continuous glucose monitoring for people with diabetes, received the US Food and Drug Administration (FDA) approval for the next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with all types of diabetes aged two years and older.&nbsp;<\/p>\n\n\n\n<p>Dexcom G7 delivers a more potent and user-friendly system with a compact, all-in-one wearable, a redesigned mobile app, and no fingersticks or scanning necessary. It is the most popular CGM brand among patients and healthcare professionals. Additionally, the Dexcom G7 provides a range of programmable alerts that can assist users to stay in range by warning them of high or low glucose readings. A predictive low alert is a feature of the system that gives users a 20-minute head start on potentially dangerous low glucose levels so they can take immediate action to prevent a hypoglycemic crisis. Dexcom G7 generates less waste than the previous Dexcom G6 CGM System because of smaller plastic components and packaging.&nbsp; The launch of Dexcom G7 in the United States is expected in early 2023.&nbsp;<\/p>\n\n\n\n<p><em>\u201cThere\u2019s a reason Dexcom has the best-selling real-time CGM on the market,\u201d <\/em>commented Kevin Sayer, chairman, president, and CEO of Dexcom<em>. <\/em>He remarked,<em> \u201cFor more than a decade, we\u2019ve pioneered generation after generation of sensing technology that consistently delivers improved accuracy, reliability, and a simpler user experience, giving people greater control of their diabetes. When we set out to design G7, our goal was simple: to make the most powerful, easy-to-use CGM available for people with diabetes, whether they have Type 1 or Type 2. G7 delivers squarely on that promise. And now that it has been cleared by the FDA, we look forward to making G7 commercially available in the coming months.\u201d&nbsp;<\/em><\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/blood-glucose-monitoring-systems-market\"><strong>Blood Glucose Monitoring Systems Market<\/strong><\/a>\u201d report, the global blood glucose monitoring systems market was valued at <strong>USD 13.06 billion<\/strong> in <strong>2021<\/strong>, growing at a CAGR of <strong>7.72%<\/strong> during the forecast period from 2022 to 2027, to reach <strong>USD 20.40 billion<\/strong> by <strong>2027<\/strong>. The blood glucose monitoring systems market is estimated to register positive revenue growth owing to the factors such as the <a href=\"https:\/\/www.delveinsight.com\/report-store\/type-1-diabetes-epidemiology-forecast\"><strong>rising prevalence of diabetes globally<\/strong><\/a> coupled with the rising geriatric population. Moreover, rising government initiatives for diabetes, and the increasing focus of manufacturers to develop technologically advanced blood glucose monitoring systems, are likely to propel the market for blood glucose monitoring systems in the upcoming years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-first-patient-enrolled-in-glioblastoma-trial-using-clearpoint-prism-neuro-laser-therapy\"><span class=\"ez-toc-section\" id=\"First_Patient_Enrolled_in_Glioblastoma_Trial_Using_ClearPoint_Prism%E2%84%A2_Neuro_Laser_Therapy\"><\/span><strong>First Patient Enrolled in Glioblastoma Trial Using ClearPoint Prism&#x2122; Neuro Laser Therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>December 12, 2022,<\/strong> ClearPoint Neuro, announced the enrolment of the first subject in a single-center, single-arm, prospective glioblastoma clinical trial for the evaluation of the ClearPoint Prism&#x2122; Neuro Laser Therapy System.&nbsp;<\/p>\n\n\n\n<p>With the application of interstitial irradiation or thermal therapy under the guidance of magnetic resonance imaging (MRI), ClearPoint Prism Neuro Laser Therapy System necrotise or coagulate soft tissues.&nbsp;<\/p>\n\n\n\n<p>Sponsored by Clinical Laserthermia Systems AB, the Safety and Feasibility of MR-guided Laser Thermal Ablation of Brain Lesions Study aims to assess the feasibility and safety of using the minimally invasive MR-guided system for ablating tumors in up to five patients with glioblastoma.<\/p>\n\n\n\n<p><em>\u201cWe are proud to support SUS Lund and CLS on this pilot study using the innovative laser therapy system to treat glioblastoma lesions,\u201d <\/em>said Joe Burnett, Ph.D., president and CEO of ClearPoint Neuro. He further added, <em>\u201cThe ClearPoint Neuro Navigation System offers an efficient one-room solution that helps neurosurgeons in the United States to accurately place laser fibres and help treat brain tumors, radiation necrosis, and epileptic foci in thousands of patients. Expanding brain and spine laser therapy treatment options for patients and neurosurgeons in the EU, and beyond, is a key priority in the years ahead.\u201d<\/em><\/p>\n\n\n\n<p>Dr. Peter Siesj\u00f6, Neurosurgeon and Principal Investigator of the study at Sk\u00e5ne University Hospital in Lund, Sweden, commented, <em>\u201cThe clinical trial with minimally invasive laser thermal treatment of patients with recurrent malignant brain tumors, glioblastoma, has now started at Sk\u00e5ne University Hospital and the treatment of the first patient could be carried out as planned. The treatment was performed, for the first time in Sweden, in a magnetic resonance imaging (MRI) suite to avoid transporting the patient between surgery and the MRI suite. \u201d<\/em><\/p>\n\n\n\n<p>According to DelveInsight\u2019s<strong> <\/strong>\u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/neurology-devices-market\"><strong>Neurology Devices Market<\/strong><\/a>\u201d report, the<strong> <\/strong>global neurology devices market is expected to grow at a CAGR of <strong>7.46%<\/strong> during the forecast period from 2022 to 2027. The neurology devices market is observing optimistic market growth due to the factors such as a rise in the regulatory approvals for neurology devices across the globe. Further, the rising prevalence of head injuries owing to accidents, workplace injuries, and others, and the rise in the geriatric population will increase the <a href=\"https:\/\/www.delveinsight.com\/blog\/key-companies-in-neurological-disorders-market\"><strong>prevalence of neurological diseases<\/strong><\/a>, thereby increasing the demand for various neurological devices across the globe. Additionally, the growing focus on improving the safety, affordability, and usability of neurology devices for end users is further expected to result in appreciable revenue growth in the neurology devices market during the forecast period (2022-2027).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-boston-scientific-announced-strategic-investment-to-acquire-majority-stake-of-acotec-scientific-holdings-limited\"><span class=\"ez-toc-section\" id=\"Boston_Scientific_Announced_Strategic_Investment_to_Acquire_Majority_Stake_of_Acotec_Scientific_Holdings_Limited\"><\/span><strong>Boston Scientific Announced Strategic Investment to Acquire Majority Stake of Acotec Scientific Holdings Limited&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> December 11, 2022, <\/strong>Boston Scientific Corporation and Acotec Scientific Holdings Limited announced that Boston Scientific will make a partial offer to acquire a majority stake, up to a maximum of 65%, of shares of Acotec.&nbsp;<\/p>\n\n\n\n<p>Acotech is a Chinese medical technology company that offers innovative medical solutions for a variety of interventional procedures including drug-coated balloons. Along with thrombus aspiration catheters and radiofrequency ablation technologies, the Acotec portfolio also comprises more than 20 other devices in various stages of development across a variety of specializations. Actotec earned sales of RMB 339 million, or roughly US$53 million, for the 12 months that ended June 30, 2022.<\/p>\n\n\n\n<p>Due to amortisation expense and acquisition-related net charges, Boston Scientific anticipates that the impact on adjusted profits per share will be insignificant in 2023 and the impact on GAAP earnings per share will be less accretive, or dilutive, as the case may be. The transaction&#8217;s conclusion, which is planned for the first half of 2023, is contingent on shareholder acceptance and approval as well as further requirements detailed in associated papers.<\/p>\n\n\n\n<p><em>&#8220;Acotec is a profitable, fast-growing company with a strong portfolio and innovative pipeline of medical technologies, and we believe this investment will generate growth opportunities for both companies,&#8221; <\/em>said Art Butcher, executive vice president and group president, MedSurg and Asia Pacific, Boston Scientific<em>.<\/em> He further commented, <em>&#8220;We expect completion of the partial offer to further strengthen our presence in China and create the potential for commercialization of Acotec products globally, providing an increased number of physicians and patients access to our robust and complementary product portfolios.&#8221;<\/em><\/p>\n\n\n\n<p>According to<strong> <\/strong>DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/interventional-radiology-devices-market\"><strong>Interventional Radiology Devices Market<\/strong><\/a>\u201d report,<strong> <\/strong>the global interventional radiology devices market is estimated to grow at a&nbsp;CAGR of <strong>5.23%<\/strong>&nbsp;during the forecast period from 2022 to 2027. The interventional radiology devices market is observing remarkable market growth due to the increasing patient pool suffering from chronic diseases such as cancer and the rising burden of the geriatric population across the globe. Additionally, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/surgical-robotic-system-market\"><strong>growing demand for minimally invasive surgeries<\/strong><\/a>, increasing technological advancements along with increasing product launches and approvals, the presence of key players in the market, and other factors will create a requisite for interventional radiology devices in the market.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-agilent-resolution-ctdx-first-receives-fda-approval-as-a-liquid-biopsy-companion-diagnostic-test-for-advanced-non-small-cell-lung-cancer\"><span class=\"ez-toc-section\" id=\"Agilent_Resolution_ctDx_FIRST_Receives_FDA_Approval_as_a_Liquid_Biopsy_Companion_Diagnostic_Test_for_Advanced_Non-small_Cell_Lung_Cancer\"><\/span><strong>Agilent Resolution ctDx FIRST Receives FDA Approval as a Liquid Biopsy Companion Diagnostic Test for Advanced Non-small Cell Lung Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> December 12, 2022, <\/strong>Agilent Technologies Inc., received the US Food and Drug Administration (FDA) clearance for Agilent Resolution ctDx FIRST. The <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-carcinoma-nsclc-epidemiology-forecast\">advanced non-small cell lung cancer patients (NSCLC) with KRAS G12C mutations<\/a><\/strong> who may benefit from treatment with KRAZATI&#x2122; (adagrasib) can be identified with the help of ctDx FIRST.\u00a0<\/p>\n\n\n\n<p>This first liquid biopsy NGS assay was created in partnership with Mirati Therapeutics and was authorized by the FDA as a CDx for the recently approved <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\">KRAZATI in advanced NSCLC<\/a><\/strong>.<\/p>\n\n\n\n<p>The comprehensive genomic profile on 109 genes across four categories of alterations\u2014single nucleotide variations (SNVs), insertions and deletions, copy number amplifications (CNAs), and fusions are included in the ctDX FIRST test result.&nbsp;<\/p>\n\n\n\n<p>Utilizing cutting-edge proprietary technology, the ctDx FIRST assay may identify genomic changes in plasma-derived circulating tumor DNA (ctDNA). About 90% of cancer patients prefer this minimally invasive method over more invasive tissue biopsy examinations. Additionally, it has a quicker turnaround time to potentially speed up therapy choices.<\/p>\n\n\n\n<p><em>\u201cCommercializing the ctDx FIRST test enables us to support clinicians to positively impact the lives of patients with advanced NSCLC,\u201d <\/em>commented Sam Raha, Agilent\u2019s President of the Diagnostics and Genomics Group.<em> <\/em>He further added,<em> &#8220;Agilent values opportunities to partner with Mirati and other pharmaceutical companies in developing clinically relevant NGS-based diagnostics that enhance confidence in targeted cancer therapy.&#8221;<\/em><\/p>\n\n\n\n<p>Kenna Anderes, Mirati\u2019s Vice President of Translational Medicine and Companion Diagnostics, said,<em> \u201cExpanding access to accurate and fast genomic profiling is an essential step to unlocking important medicines for patients in desperate need.\u201d <\/em>He remarked,<em> \u201cWe appreciate the opportunity to partner with companies like Agilent which are committed to creating more opportunities for \u2018decision medicine\u2019 for people living with cancer.\u201d<\/em>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/liquid-biopsy-in-cancer-diagnostics-market\"><strong>Liquid Biopsy in Cancer Diagnostics<\/strong><strong> <\/strong><strong>Market<\/strong><\/a>\u201d&nbsp; report,<strong> <\/strong>the liquid biopsy in cancer diagnostics market was valued at <strong>USD 7.64 billion<\/strong> in <strong>2021,<\/strong> growing at a CAGR of <strong>16.64%<\/strong> during the forecast period from 2022 to 2027 to reach <strong>USD 19.24 billion<\/strong> by <strong>2027<\/strong>. The demand for liquid biopsy in cancer diagnostics is primarily attributed to the increasing prevalence of different cancer types such as lung, breast, stomach, and others. In addition, the increasing demand for precision medicine and technical innovation in product development, among other factors, are anticipated to drive the market of liquid biopsy in cancer diagnostics during the forecast period from 2022 to 2027.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BioGX Announced Ex-US Commercial Launch of \u2018pixl&#x2122;\u2019 Portable qPCR Platform On December 8, 2022, BioGX, a global provider of easy molecular diagnostic solutions, announced the Ex-US commercial release of BioGX&#8217;s portable pixl&#x2122; qPCR real-time PCR platform for use with BioGX CE-IVD approved assays.&nbsp; This opens up access to the world and complements the recent US [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":20161,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[19330,19881,20029,18984,20033,2753,17021,16975,18799,20035,20031,20030,420,2242],"industry":[17226],"therapeutic_areas":[17240,17245],"class_list":["post-20157","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-clinical-diagnostics","tag-clinical-diagnostics-market","tag-foot-and-ankle-devices","tag-foot-and-ankle-devices-market","tag-interventional-radiology-devices","tag-medical-device","tag-medical-devices-market","tag-medtech-market","tag-medtech-news","tag-medtech-news-and-updates","tag-neurology-devices","tag-neurology-devices-market","tag-news","tag-polymerase-chain-reaction","industry-medical-devices","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | BioGX, Stryker, Boston Scientific, Agilent, DexCom<\/title>\n<meta name=\"description\" content=\"Dexcom G7 CGM System; ClearPoint Neuro\u2019s Prism Neuro Laser Therapy; BioGX\u2019s \u2018pixl\u2019 qPCR Platform; Stryker\u2019s Citrefix Suture; Agilent\u2019s Liquid\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biogx-stryker-dexcom-agilent\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | BioGX, Stryker, Boston Scientific, Agilent, DexCom\" \/>\n<meta property=\"og:description\" content=\"Dexcom G7 CGM System; ClearPoint Neuro\u2019s Prism Neuro Laser Therapy; BioGX\u2019s \u2018pixl\u2019 qPCR Platform; Stryker\u2019s Citrefix Suture; Agilent\u2019s Liquid\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biogx-stryker-dexcom-agilent\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-15T12:15:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T07:45:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/15174134\/MedTech-News-for-BioGX-Stryker-Boston-Scientific-Agilent-DexCom.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | BioGX, Stryker, Boston Scientific, Agilent, DexCom","description":"Dexcom G7 CGM System; ClearPoint Neuro\u2019s Prism Neuro Laser Therapy; BioGX\u2019s \u2018pixl\u2019 qPCR Platform; Stryker\u2019s Citrefix Suture; Agilent\u2019s Liquid","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biogx-stryker-dexcom-agilent","og_locale":"en_US","og_type":"article","og_title":"MedTech News | BioGX, Stryker, Boston Scientific, Agilent, DexCom","og_description":"Dexcom G7 CGM System; ClearPoint Neuro\u2019s Prism Neuro Laser Therapy; BioGX\u2019s \u2018pixl\u2019 qPCR Platform; Stryker\u2019s Citrefix Suture; Agilent\u2019s Liquid","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biogx-stryker-dexcom-agilent","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-12-15T12:15:13+00:00","article_modified_time":"2024-09-18T07:45:19+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/15174134\/MedTech-News-for-BioGX-Stryker-Boston-Scientific-Agilent-DexCom.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biogx-stryker-dexcom-agilent","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biogx-stryker-dexcom-agilent","name":"MedTech News | BioGX, Stryker, Boston Scientific, Agilent, DexCom","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biogx-stryker-dexcom-agilent#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biogx-stryker-dexcom-agilent#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/15174134\/MedTech-News-for-BioGX-Stryker-Boston-Scientific-Agilent-DexCom.png","datePublished":"2022-12-15T12:15:13+00:00","dateModified":"2024-09-18T07:45:19+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Dexcom G7 CGM System; ClearPoint Neuro\u2019s Prism Neuro Laser Therapy; BioGX\u2019s \u2018pixl\u2019 qPCR Platform; Stryker\u2019s Citrefix Suture; Agilent\u2019s Liquid","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biogx-stryker-dexcom-agilent"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-biogx-stryker-dexcom-agilent#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/15174134\/MedTech-News-for-BioGX-Stryker-Boston-Scientific-Agilent-DexCom.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/15174134\/MedTech-News-for-BioGX-Stryker-Boston-Scientific-Agilent-DexCom.png","width":772,"height":482,"caption":"MedTech News for BioGX, Stryker, Boston Scientific, Agilent, DexCom"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/15174134\/MedTech-News-for-BioGX-Stryker-Boston-Scientific-Agilent-DexCom-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Clinical Diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">clinical diagnostics market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Foot and Ankle Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Foot and Ankle Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Interventional Radiology Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech News<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech News and Updates<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neurology Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neurology Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">polymerase chain reaction<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Clinical Diagnostics<\/span>","<span class=\"advgb-post-tax-term\">clinical diagnostics market<\/span>","<span class=\"advgb-post-tax-term\">Foot and Ankle Devices<\/span>","<span class=\"advgb-post-tax-term\">Foot and Ankle Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Interventional Radiology Devices<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech News<\/span>","<span class=\"advgb-post-tax-term\">MedTech News and Updates<\/span>","<span class=\"advgb-post-tax-term\">Neurology Devices<\/span>","<span class=\"advgb-post-tax-term\">Neurology Devices Market<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">polymerase chain reaction<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Dec 15, 2022","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Dec 15, 2022 5:45 pm","modified":"Updated on Sep 18, 2024 1:15 pm"},"featured_img_caption":"MedTech News for BioGX, Stryker, Boston Scientific, Agilent, DexCom","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=20157"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20157\/revisions"}],"predecessor-version":[{"id":29588,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20157\/revisions\/29588"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/20161"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=20157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=20157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=20157"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=20157"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=20157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}